A Randomized Open-Label Phase III Trial Evaluating the Addition of Denosumab to Standard First-Line Treatment in Advanced NSCLC: The European Thoracic Oncology Platform (ETOP) and European Organisation for Research and Treatment of Cancer (EORTC) SPLENDOUR Trial

Peters, S; Danson, S; Hasan, B; Dafni, U; Reinmuth, N; Majem, M; Tournoy, KG; Mark, MT; Pless, M; Cobo, M; Rodriguez-Abreu, D; Falchero, L; Moran, T; Granados, ALO; Monnet, I; Mohorcic, K; Sureda, BM; Betticher, D; Demedts, I; Macias, JA; Cuffe, S; Luciani, A; Sanchez, JG; Curioni-Fontecedro, A; Gautschi, O; Price, G; Coate, L; von Moos, R; Zielinski, C; Provencio, M; Menis, J; Ruepp, B; Pochesci, A; Roschitzki-Voser, H; Besse, B; Rabaglio, M; O’Brien, MER; Stahel, RA – 2020 – 10.1016/j.jtho.2020.06.011